###begin article-title 0
Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 947 951 947 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
Real-time quantitative PCR (RQ-PCR) forms the basis of many breast cancer biomarker studies and novel prognostic assays, paving the way towards personalised cancer treatments. Normalisation of relative RQ-PCR data is required to control for non-biological variation introduced during sample preparation. Endogenous control (EC) genes, used in this context, should ideally be expressed constitutively and uniformly across treatments in all test samples. Despite widespread recognition that the accuracy of the normalised data is largely dependent on the reliability of the EC, there are no reports of the systematic validation of genes commonly used for this purpose in the analysis of gene expression by RQ-PCR in primary breast cancer tissues. The aim of this study was to identify the most suitable endogenous control genes for RQ-PCR analysis of primary breast tissue from a panel of eleven candidates in current use. Oestrogen receptor alpha (ESR1) was used a target gene to compare the effect of choice of EC on the estimate of gene quantity.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC</italic>
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0</italic>
###xml 84 87 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB</italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1 </italic>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4) </italic>
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB</italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL </italic>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary breast cancer tissues. Gene expression data was analysed using two different statistical models. MRPL19 and PPIA were identified as the most stable and reliable EC genes, while GUSB, RPLP0 and ABL were least stable. There was a highly significant difference in variance between ECs. ESR1 expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
We have validated two endogenous control genes, MRPL19 and PPIA, for RQ-PCR analysis of gene expression in primary breast tissue. Of the genes in current use in this field, the above combination offers increased accuracy and resolution in the quantitation of gene expression data, facilitating the detection of smaller changes in gene expression than otherwise possible. The combination identified here is a good candidate for use as a two-gene endogenous control in a broad spectrum of future research and diagnostic applications in breast cancer.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 949 950 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 58 63 <span type="species:ncbi:9606">women</span>
###xml 137 142 <span type="species:ncbi:9606">women</span>
Breast cancer is the most common form of malignancy among women in almost all of Europe and in North America. Each year over one million women worldwide are diagnosed with the disease and it causes over 400,000 deaths annually. Much of the current translational research in this area is based on "transcriptomics", the elucidation of the transcriptional programs underlying disease initiation, promotion and progression, through tumour gene expression profiling. Real-time quantitative PCR (RQ-PCR) [1,2] is one of the most sensitive and specific quantitation methods for gene expression analysis and is firmly established as a mainstream research tool [3-5]. With the development of high throughput and reliable instrumentation, improved detection chemistries, more efficient protocols and appropriate analysis software, RQ-PCR has become the basis of many breast cancer biomarker studies as well as several novel diagnostic and prognostic assays [6-12]. In addition, RQ-PCR is used to validate microarray expression profiles and quantify genes of interest identified from those analyses.
###end p 9
###begin p 10
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The most commonly used method to quantify gene expression involves the analysis of target gene expression relative to a control gene. As in other relative gene expression analysis techniques such as Northern blotting and ribonuclease protection assays (RPAs), normalisation of RQ-PCR data is required to control for variation introduced during the steps from RNA extraction to quantitation, especially to control for differences in the quantity and quality of RNA used in reactions [13]. The use of endogenous control (EC) genes, known variously as housekeepers, reference or simply control genes is based on the principle that these genes are expressed constitutively and uniformly in all test samples, so that expression of the target gene can be normalised against them to control for systematic variation in sample handling. Results are then expressed as the ratio of target gene expression relative to the EC gene. In many cases, control genes are inherited from earlier studies using less sensitive forerunner techniques such as Northern blotting and little if any consideration has been paid to validating these genes as controls for specific experiments.
###end p 10
###begin p 11
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 166 170 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 367 369 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 370 372 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 526 531 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 599 601 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 654 659 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 704 706 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Two of the most commonly used endogenous control genes for breast cancer gene expression studies are glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB) but their reliability in this context has not been demonstrated. In some studies the use of either gene may be inappropriate, as these genes have been implicated in aspects of disease aetiology [14-20]. For example, bisphosphonates; used to inhibit bone resorption in diseases including osteoporosis, Paget's disease and metastatic breast cancer, target GAPDH, decreasing its expression in both breast and prostate cell lines [21], while the actin filament protein family, of which ACTB is a member, may be modulated in malignancy [22] particularly during processes involving reorganisation of the cytoskeleton such as invasion and migration.
###end p 11
###begin p 12
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 921 982 921 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1</italic>
###xml 984 989 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4</italic>
###xml 1128 1132 1128 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
The precision of the estimate of change in target gene expression is dependent on the stability of the endogenous control, the variability associated with the target gene and any covariance between the two. Thus the use of non-validated endogenous control genes results in, at best, unreliable data. It is now recognised that a universal, invariably expressed gene is unlikely to exist [23] and may not exist even within individual tissue or cell types. The goal therefore is to identify the most reliable gene or set of genes as endogenous controls for a particular experiment. As a result of this, several groups have developed statistical models and software programs for the analysis of candidate gene stability. The aim of this study was to identify the most stable endogenous control genes from a panel of eleven candidates commonly used as endogenous controls in the context of, but not limited to, breast cancer: GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1, PSMC4, for the quantification of gene expression by relative comparative RQ-PCR in primary breast cancer tissues. The oestrogen receptor alpha (ESR1) transcript, a gene of special significance in breast cancer, was used as a target gene to compare the effect of choice of EC on the estimate of gene quantity.
###end p 12
###begin title 13
Results
###end title 13
###begin p 14
###xml 205 267 205 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 </italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4</italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
To identify suitable EC genes for breast cancer gene expression studies in fresh-frozen primary tissue, a panel of 11 genes commonly used as ECs was selected from the literature for analysis of stability: GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4. Genes were analysed in tumours recovered from patients with benign or malignant breast disease using RQ-PCR. Stability of candidate EC genes was analysed using two statistical analysis tools, geNorm and NormFinder, which employ different statistical models to define the most reliable EC genes for normalisation. The effect of choice of EC gene on target gene expression was analysed using ESR1 as target.
###end p 14
###begin title 15
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
Range of expression of candidate EC genes and ESR1
###end title 15
###begin p 16
###xml 40 42 40 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 143 145 143 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 192 196 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 227 233 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 234 241 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 280 284 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 364 366 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 383 406 379 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M, RPLP0, GAPDH, PPIA</italic>
###xml 448 450 444 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 467 503 463 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4, ABL, GUSB, TFRC, PUM1, HPRT1 </italic>
###xml 507 513 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 532 537 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 567 569 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
The candidate ECs displayed a range of Ct values. Mean Ct values per gene and the range of Ct values for each gene are shown in Table 1. Mean Ct values ranged from 19.13 (+/- 0.21 s.e.m.) for B2M to 26.48 (+/- 0.15 s.e.m.) for MRPL19.MRPL19 showed the narrowest range followed by PPIA. The genes broadly fell into two categories, those highly expressed with mean Ct values of 19-20 (B2M, RPLP0, GAPDH, PPIA) and moderate abundance genes with mean Ct values of 23-26 (PSMC4, ABL, GUSB, TFRC, PUM1, HPRT1 and MRPL19). The target gene ESR1 showed the broadest range of Ct values (10.35) from 17.10-27.45.
###end p 16
###begin p 17
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESRI</italic>
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1</italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 253 255 253 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 262 280 262 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M, RPLP0, GAPDH </italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 315 317 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 324 360 324 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4, ABL, GUSB, TFRC, PUM1, HPRT1 </italic>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 397 399 397 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
Cycle threshold (Ct) values of candidate EC genes and ESRI. Among the candidate ECs, MRPL19 and PPIA showed the smallest range in Ct values while GAPDH, HPRT1, and RPLP0 showed the greatest. Candidates fell into two groups in terms of abundance, high (Ct 19-20; B2M, RPLP0, GAPDH and PPIA) and moderate abundance (Ct 23-26; PSMC4, ABL, GUSB, TFRC, PUM1, HPRT1 and MRPL19). ESR1 ranged over 10.35 Ct values
###end p 17
###begin p 18
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 59 62 59 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 160 162 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 251 253 251 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
With conversion of Ct values to relative quantity values (QRel.), there was no difference in candidate EC gene quantities between benign and malignant tissues (P > 0.05; Fig. 1a). There was however, a significant difference in variance between genes (P = 0.001; Fig. 1b) indicative of differing stabilities of the candidates.
###end p 18
###begin p 19
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative quantity and variation associated with each candidate EC</bold>
###xml 117 179 117 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 259 262 259 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 267 275 267 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;Ct</sup>
###xml 441 443 437 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 516 578 512 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 </italic>
###xml 582 588 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 690 692 682 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 747 750 739 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 755 763 747 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;Ct</sup>
###xml 855 857 843 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 885 890 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0</italic>
###xml 892 896 880 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRFC</italic>
###xml 898 904 886 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 908 914 896 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 958 965 946 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 969 973 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
Relative quantity and variation associated with each candidate EC. a) Quantity of candidate endogenous control genes GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4 in benign and malignant breast tumour tissue relative to calibrator (QRel. = E-DeltaCt). Boxplot shows median value, interquartile-range box and outliers (*). Within gene there was no difference in gene quantities between benign and malignant tissues (P > 0.05). b) Variation associated with candidate endogenous control genes GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4 in all breast tumours relative to calibrator. Relative gene expression was calculated using the DeltaCt method and corrected for efficiency of amplification (QRel. = E-DeltaCt). There was a significant difference in variance associated with relative gene expression (P = 0.001) with genes such as RPLP0, TRFC, HPRT1 and GAPDH showing greater variance than genes such as MRPL19 and PPIA.
###end p 19
###begin title 20
Analysis of EC gene stability
###end title 20
###begin p 21
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The significant difference in EC variability demonstrated the necessity to validate their use in this context. Expression stability was analysed using the two softwares geNorm [24,25] and NormFinder [26].
###end p 21
###begin p 22
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 314 316 314 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 389 391 389 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 477 481 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 483 486 483 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 488 493 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1</italic>
###xml 495 501 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC</italic>
###xml 518 520 518 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0</italic>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 623 626 623 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL</italic>
###xml 635 637 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 753 755 753 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 955 959 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL </italic>
###xml 963 968 963 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 1072 1079 1072 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 1083 1088 1083 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
GeNorm uses a pair-wise comparison-based model to select from a panel of candidate EC genes, the gene-pair showing least variation in expression ratio across samples. It calculates a measure of gene stability (M) of each gene based on the average pairwise variation between all tested genes. Genes with the lowest M values are those demonstrating most stable expression. Table 2 shows the M values for all tested genes. Eight of the eleven genes analysed; PPIA, MRPL19, GAPDH, PUM1, B2M, HPRT1, PSMC4 and TFRC, showed M values less than the geNorm default threshold of 1.5, while the three remaining genes; RPLP0, GUSB and ABL, showed M values greater than that threshold. In a stepwise progression, geNorm excludes the least stable gene, recalculating M for the remaining genes, resulting in the characterisation of the stability of each gene on a ranked scale and ultimately the identification of the two most stably expressed genes (Fig. 2a). As shown,ABL and GUSB were the first and second genes respectively excluded from the analysis on the basis of instability and MRPL19 and PPIA were identified as most stable gene-pair.
###end p 22
###begin p 23
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GeNorm analysis of the candidate EC genes</bold>
###xml 193 195 193 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 268 270 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 604 606 604 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V </italic>
GeNorm analysis of the candidate EC genes. Results are presented as per the output file of the geNorm programme [24]. (a) Stepwise exclusion of the least stable genes. The gene stability value M is based on the average pairwise variation between all tested genes. Low M values characterise genes with greater stability, thus the x-axis from left to right indicates the ranking of the EC genes according to expression stability and the y-axis indicates the stability measure, M. (b) Determination of the optimal number of ECs for normalisation. The recommended upper limit of the pairwise variation value V is set at 0.15 but in meeting this criterion, sample availability, the practicality of using multiple EC genes and the degree of required resolution must be considered.
###end p 23
###begin p 24
Expression stability values of EC genes calculated by geNorm and NormFinder programmes
###end p 24
###begin p 25
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
bHigh expression stability is indicated by a low stability value. For geNorm, stability is based on an estimate of the pairwise variation (M) relative expression while for NormFinder, stability is based on combined inter- and intra-group variation.
###end p 25
###begin p 26
###xml 186 188 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V </italic>
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 219 224 219 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n + 1</sub>
###xml 256 258 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 264 269 264 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n + 1</sub>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 486 489 486 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 492 498 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1 </italic>
###xml 522 526 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 602 607 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 644 650 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 658 668 658 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M GAPDH </italic>
###xml 672 676 672 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 718 725 718 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 735 737 735 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
GeNorm also calculates a normalisation factor (NF) required to determine the optimal number of EC genes required for accurate normalisation. This factor is calculated using the variable V as the pairwise variation (Vn/Vn + 1) between two sequential NFs (NFn and NFn + 1). To meet the recommended cut off V-value of 0.15, the point at which it is unnecessary to include additional genes in a normalisation strategy [24], the programme indicated the use of 5 of the six most stable genes i.e., MRPL19, PPIA, GAPDH, PUM1 and B2M (Fig. 2b). However, there was no significant effect on relative quantity of ESR1 expression using the 5 gene panel of MRPL19, PPIA, B2M GAPDH and PUM1, compared to the two-gene combination of MRPL19 and PPIA (P > 0.05).
###end p 26
###begin p 27
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 304 311 304 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRLP19 </italic>
Stability of gene expression was also analysed using NormFinder [26]. This programme uses a combined estimate of the intra- and inter-group variation to determine the most stably expressed candidate EC gene and gene-pair. Table 2 shows the ranking of the candidates. As for geNorm, NormFinder identified MRPL19 and PPIA as the most stable pair of genes and MRLP19 as the single most stable gene.
###end p 27
###begin title 28
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
Associations between candidates EC genes and ESR1
###end title 28
###begin p 29
###xml 429 432 429 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC </italic>
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC </italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 521 523 521 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 531 533 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 545 551 545 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 576 580 576 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 583 585 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 593 595 593 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 669 672 669 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 677 682 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL </italic>
###xml 717 721 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL </italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 744 746 744 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 753 755 753 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 813 820 813 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 823 828 823 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 829 831 829 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The geNorm programme assumes no co-regulation of candidate ECs as obviously this would lead to an erroneous choice of optimum normaliser pair. As stated above, to our knowledge the candidate ECs tested in this study are functionally independent. In addition co-variance between target gene and EC would affect results. Regression analysis demonstrated significant, negative, linear associations between the relative quantities (QRel.) of the target gene, ESR1 and two commonly used ECs; TFRC (TFRC = 0.079 - 0.272 ESR1; R2 = 0.18; P < 0.05) and HPRT1 (HPRT1 = - 0.202 - 0.386 ESR1; R2 = 0.35; P = 0.001). In addition there was a significant linear association between QRel. of ESR1 and ABL described by the equation: ABL = 0.044 + 0.290 ESR1; R2 = 0.21;P = 0.012. There was no association between ESR1 and either MRPL19 or PPIA (P > 0.05).
###end p 29
###begin title 30
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
Effect of EC on ESR1 relative gene expression
###end title 30
###begin p 31
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 70 72 70 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRL19 </italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL</italic>
###xml 475 478 475 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB</italic>
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1</italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4</italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC</italic>
###xml 580 587 580 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 623 630 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 642 644 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 816 821 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 897 899 897 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
There was no effect of choice of EC on the relative quantity of ESR1 (P > 0.05) probably due to the large variation associated with the expression of ESR1 compared to any of the EC genes as shown in Fig. 3. However, there was a significant effect of EC gene on the estimate of the error associated with relative gene expression (P < 0.05). The magnitude of the error was significantly reduced using MRL19 and PPIA as a combined endogenous control compared to the use of ABL, B2M, GAPDH, GUSB, HPRT1, PSMC4, PPIA, PUM1, RPLP0 and TFRC. While there was no difference in error using MRPL19 and PPIA in combination compared to MRPL19 on its own (P > 0.05), there was a trend towards a reduction in the estimate of the error using the combined normalising factor. There was a significant increase in relative quantity of ESR1 in malignant versus benign breast tissues compared to normal breast tissue (P < 0.01; Fig. 4).
###end p 31
###begin p 32
###xml 75 78 75 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 83 91 83 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;Ct</sup>
###xml 0 92 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantity of all genes expressed in breast tissues relative to calibrator (Q<sub>Rel</sub>. = E<sup>-&#916;Ct</sup>)</bold>
Quantity of all genes expressed in breast tissues relative to calibrator (QRel. = E-DeltaCt). A pool of cDNA from two normal tissues was used as calibrator.
###end p 32
###begin p 33
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative quantity of oestrogen receptor alpha mRNA (<italic>ESR1</italic>) in benign and malignant breast tumour tissue</bold>
###xml 227 234 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 245 248 245 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 253 267 253 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 397 402 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 419 421 409 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 552 554 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 624 630 614 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRL19 </italic>
###xml 634 639 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 710 716 700 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
Relative quantity of oestrogen receptor alpha mRNA (ESR1) in benign and malignant breast tumour tissue. Quantity of gene expression was calculated relative to each candidate endogenous control gene and to the geometric mean of MRPL19 and PPIA (QRel. = E-DeltaDeltaCt +/- s.e.m.). A pool of cDNA from two normal tissues was used as calibrator. There was no effect of EC on the relative quantity of ESR1 in either group (P > 0.05), however, there was a significant effect of EC gene on the estimate of the error associated with relative gene expression (P < 0.05). The error was significantly reduced using the combination of MRL19 and PPIA compared to the use of all EC genes individually with the exception of MRPL19.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
To our knowledge this is the first systematic evaluation of the reliability of a large number of genes used as endogenous controls for RQ-PCR analysis in breast cancer studies. The literature cites just two articles in relation to the evaluation of EC genes for breast cancer [27,28]. However, one study characterised ECs not in primary breast tissues but in cell lines [27] and the other, while employing primary breast tissues, compared just two commonly used EC genes with other genes selected from a microarray dataset of breast cancer tissues and cell lines, as well as cell lines of different origins [28].
###end p 35
###begin p 36
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">type</italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 761 764 761 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL</italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
Quantitative PCR is the basis of most nucleic acid-based breast cancer biomarker studies and its potential clinical utility is foretold by the development of the Oncotype Dx assay (Genomic Health). This 21-gene assay can predict metastatic recurrence [11] and magnitude of response to chemotherapy [29] in Tamoxifen-treated ER-positive early breast cancer patients. RQ-PCR will undoubtedly feature prominently in the move toward personalised medicine so the necessity of validating ECs in clinical samples as opposed to cell lines is clear. The diversity of the tissues used in this study in terms of histological and clinical parameters (Table 3) makes the results of interest to a broad spectrum of the breast cancer research community. With the exception of ABL, used as an EC in other settings [30], genes were selected for evaluation based their prior use in breast cancer studies, to determine the most reliable EC of those used in this field. Certain genes were excluded based on evidence that their use in this context is inappropriate [20,22,31-33].
###end p 36
###begin p 37
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 112 119 <span type="species:ncbi:9606">patient</span>
Clinical and histological data relating to the benign (Ben.) and malignant (Mal.) breast tissues. Data includes patient menopausal status and histological type, and tumour size, T, N, M, UICC stage, grade, ER, PR and HER2/neu status and intrinsic subtype of malignant tissues where available
###end p 37
###begin p 38
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
Abbreviations: T: size or extent of primary tumour; N: spread to regional lymph nodes; M: distant metastasis; UICC, tumour stage according to the International Union Against Cancer TNM classification; ER: oestrogen receptor status; PR: progesterone receptor status; HER2/neu: v-erb-b2 erythroblastic leukaemia viral oncogene status.
###end p 38
###begin p 39
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 812 813 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1004 1005 1004 1005 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 1131 1133 1131 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
Validation of EC genes raises the circular issue of how to normalise normalising genes. This issue governs the validity of the conclusions of such studies so at each stage of this experiment sources of non-biological variation were minimised and data were scaled relative to a calibrator. For example, RNA integrity, quality and purity were stringently analysed. A threshold RIN value of 7 was applied, below which samples were excluded from analysis. This aspect is of importance given the relationship between RNA integrity and expression quantitation [34-36]. Duplicate cDNA reactions were performed and genes were amplified in triplicate using more stringent cut-offs for replicate variability than recommended elsewhere [37]. In addition, the efficiency of amplification of each assay was determined (Table 4) and data were corrected appropriately. Determination of assay efficiency is critical in comparing gene expression [38] but has not been addressed in similar studies [39]. Cycle threshold (Ct) data were scaled relative a pooled normal tissue calibrator. Similar studies describe the comparison of genes based on raw Ct values [40,41], an inappropriate approach as discussed below and elsewhere [36].
###end p 39
###begin p 40
Details of gene-specific RQ-PCR assays
###end p 40
###begin p 41
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 379 381 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRFC</italic>
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 441 447 441 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 484 485 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 486 487 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 490 497 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
There was no effect of tissue type on EC expression, validating comparison of their stability. This is an essential but often overlooked precursor analysis when using geNorm and NormFinder [42] since these methodologies assume the candidates are not differentially expressed between experimental groups. There was however a significant difference in variance between candidates (P = 0.001; Fig. 1), with genes such as RPLP0, TRFC, HPRT1 and GAPDH showing greater variance than others e.g., MRPL19 and PPIA. Since the resolution of RQ-PCR is defined by the variance associated with the EC [13] these results emphasise the necessity to evaluate and validate EC genes.
###end p 41
###begin p 42
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1082 1089 1082 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 1093 1098 1093 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 1129 1134 1129 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0</italic>
###xml 1136 1141 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 1145 1149 1145 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL </italic>
###xml 1269 1271 1269 1271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1285 1286 1285 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1323 1325 1323 1325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1386 1387 1386 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1388 1389 1388 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1392 1397 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 1453 1454 1453 1454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 1628 1633 1628 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
A single universal EC is unlikely to exist [43] and since the function of most genes is largely unknown it is impossible to predict their expression under different experimental conditions. The use of more than one EC hedges the bet and increases the accuracy of quantitation compared to the use of a single EC [13,24,26,36,44]. Studies show substantial errors, up to 6.5-fold, in expression quantitation using single as opposed to multiple EC genes [24]. In this study, stability of expression was analysed using two distinct statistical models, a pairwise comparison model, geNorm, and an ANOVA-based model, NormFinder. The geNorm applet selects from a panel of genes, the pair showing least variation in expression ratio across samples and estimates the minimum number of genes required for optimal normalisation. NormFinder estimates stability values for ECs considering combined intra- and inter-group variation and identifies the most stable gene and gene-pair, where the stability of the pair exceeds that of the single gene. Despite their differences both models identified MRPL19 and PPIA as the most reliable ECs while RPLP0, GUSB and ABL were least reliable. This result reflects those of the equality of variance analysis and, broadly, ranking by range of Ct values (Table 2). However, the ranking of genes by Ct range and by the model-based methods differed for some genes e.g., GAPDH, demonstrating the necessity to scale and correct raw Cts for amplification efficiency before analysis. GeNorm indicated that optimal normalisation could be achieved using the five most stable genes but there was no difference in ESR1 gene expression using this approach as opposed to the two-gene combination. While it is not known whether this would hold for other less variable target genes, cost and sample availability are limiting factors for most studies so the two-gene combination may be more practical for most applications.
###end p 42
###begin p 43
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 621 626 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
The effect of using less stable ECs was assessed using ESR1 as a target gene. Due to the high variability of the expression of this gene (Fig. 4) there was no effect of EC on quantitation. Without further discussion of the relevance of the differential expression of ESR1 in benign and malignant tissues; a gene whose role in breast cancer is widely appreciated, it is likely that had the target gene shown a more discreet change in gene expression, an effect of EC on quantitation would have been apparent. There was however a clear tendency for ESR1 expression to change depending on EC (Fig. 4). In the benign samples ESR1 could be made to appear up- or down-regulated depending on EC, while its expression in the malignant samples could be numerically altered by one order of magnitude - artifactual results due simply to the choice of EC. Clearly this type of error is unacceptable, especially in the analysis of markers for potential clinical application.
###end p 43
###begin p 44
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 787 794 787 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 838 843 838 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Furthermore, there was a significant effect of EC on the magnitude of the error associated with the estimate of ESR1 expression. The use of the MRPL19, PPIA combination minimised the error compared to all other ECs with the exception of MRPL19. Apart from the fact that the use of single EC genes can compromise data as already described, the use of either gene alone is not recommended for two further reasons. Firstly, geNorm identified them based on a pairwise comparison model so their individual use is inconsistent with that analysis method. As shown in Fig. 4, ESR1 expression can be made numerically increase or decrease in the benign groups if these genes are used singly. Secondly, stability, as assessed by NormFinder, increased roughly 30 percentage points, from 0.105 using MRPL19 alone to 0.072 using it in combination with PPIA indicating improved reliability of the two-gene combination [26].
###end p 44
###begin p 45
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF3A1</italic>
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSMC4 </italic>
###xml 584 588 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PUM1</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 826 831 826 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
###xml 862 864 862 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1401 1403 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
One previous study analysed EC stability in primary breast tissue [28]. That study compared two traditionally used ECs, GAPDH and ACTB and four genes identified in microarray studies [45,46]: MRPL19, PUM1, PSMC4 and SF3A1. The authors recommended MRPL19 be used with PSMC4 and PUM1. However, in the present study, PPIA, which was not assessed by Szabo and colleagues, showed greater stability than PSMC4 and PUM1. Of the genes analysed in this study, PPIA ranked first and second by Normfinder and geNorm respectively compared to fifth and seventh for PSMC4 and eighth and fourth for PUM1. The reason(s) PPIA did mot emerge as a candidate in Szabo and colleagues' microarray study is unclear. As part of their selection procedure, data was filtered to remove near background signals from low abundance genes yet in this study PPIA showed the third highest mean Ct value. Cohort-specific effects are also unlikely since the tissues are broadly similar in terms of their clinical and histological parameters. Apart from the obvious differences in the quantitative capacities of microarray and RQ-PCR technology, a possible explanation is that the cohort from which these authors selected their candidates was not breast cancer-specific and included tissue from metastatic breast cancer lymph nodes and cell lines from an assortment of origins including dermal, leukemic, umbilical and melanoma samples [46].
###end p 45
###begin p 46
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 467 472 467 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC</italic>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 517 520 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL</italic>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
This study also analysed associations between genes. An assumption of the geNorm model is that candidate ECs are not co-regulated yet the analysis of such genes by that method would lead to an erroneous choice of best gene-pair. To our knowledge the EC genes evaluated here are functionally independent as shown in Table 4. In addition, covariance of target and EC is clearly unacceptable. However, regression analysis showed significant linear relationships between ESR1 and three of the candidates: TFRC, HPRT1 and ABL. Approximately two thirds of breast tumours are oestrogen-dependent and the number of genes whose expression is known to be, or likely to be mediated through the receptor is sizeable [47]. This makes analysis of associations between oestrogen-responsive target and control genes of particular importance in breast cancer studies. Although there is little evidence that these genes are regulated by oestrogen, the results suggest that aside from their poor stability it would be wise not to use them as ECs in the analysis of oestrogen-responsive breast cancer.
###end p 46
###begin p 47
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Despite the clear increase in accuracy afforded by the use of more than one validated EC gene, a recent survey of working practices indicated that over half of those polled continue to use one reference gene and that two thirds of these do not validate that gene [48]. Obviously levels of awareness and/or willingness to address this issue must be improved.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPIA </italic>
The current emphasis on personalised cancer treatment has resulted in the development of prognostic and predictive multi-gene RQ-PCR assays. However, with such developments comes the demand for greater accuracy and resolution of gene expression quantitation. In this study we have validated two genes, MRPL19 and PPIA as EC candidates for RQ-PCR analysis of primary breast tissue using two different statistical models and demonstrate that of the genes in current use in this field, the above gene combination offers increased accuracy and resolution in the relative quantitation of gene expression data. The genes identified should be of use in a broad spectrum of translational research and diagnostic applications in breast cancer.
###end p 49
###begin title 50
Methods
###end title 50
###begin title 51
Breast tissue samples
###end title 51
###begin p 52
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 712 719 <span type="species:ncbi:9606">patient</span>
Primary breast tumour tissues (n = 27) were obtained from patients during primary curative resection, at Galway University Hospital, Galway, Ireland. Samples were categorised into benign (n = 6) or malignant groups (n = 21) according to analysis of standard histopathological parameters. Clinical data relating to the tumour tissues used in this study are shown in Table 3. RNA from normal tissues, recovered from patients undergoing reduction mastopexy were used as calibrator samples for comparative relative RQ-PCR (n = 2). After excision, tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80degreesC until RNA extraction. Prior written and informed consent was obtained from each patient and the study was approved by the ethics review board of Galway University Hospital. Clinical data were obtained from the Breast Cancer Database at the Department of Surgery, Galway University Hospital.
###end p 52
###begin title 53
Candidate endogenous control genes
###end title 53
###begin p 54
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19 </italic>
###xml 310 313 310 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
Eleven commonly used candidate endogenous control genes were selected for analysis (Table 4). To our knowledge, all genes are constitutively expressed in breast cancer tissues and all have independent cellular functions and are assumed not to be co-regulated. Only RPLP0 and MRPL19 share a molecular function, i.e., protein biosynthesis.
###end p 54
###begin title 55
Minimisation of non-biological variation
###end title 55
###begin p 56
While target gene expression is normalised using EC genes to correct for variation introduced during sample processing using, this is obviously not possible in EC validation studies. Since this critical issue governs the reliability of the data generated and the validity of the conclusions it was addressed as described below.
###end p 56
###begin p 57
###xml 1210 1211 1210 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1236 1237 1236 1237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 427 433 <span type="species:ncbi:9606">person</span>
Firstly, while it was not possible to control for variation in the acquisition of clinical samples collected over a number of years, every effort was made to minimise systematic variation downstream of sample acquisition. All equipment and instruments were calibrated before use. Benign and malignant samples were homogenised separately but on the same day. All RNA was extracted using the same protocol and reagent lot by one person to avoid batch-to-batch variation. Where possible, two extractions from separate areas of the each tissue sample were pooled to control for tissue heterogeneity. RNA integrity and purity were stringently analysed as described below. Duplicate cDNA reactions were performed to minimise variation from the reverse transcription step. No-RT controls were included with each batch of cDNA synthesised. All PCR reactions were performed on the same pool of aliquotted cDNA and no-template controls were included in each run for each gene. Appropriate inter-assay controls were included in each run. In addition, the efficiency of amplification was calculated for each assay and expression results were corrected for the small differences in efficiency observed between genes (Table 4). All cycle threshold (Ct) data was scaled relative to a calibrator sample amplified using the same gene.
###end p 57
###begin title 58
Total RNA Isolation
###end title 58
###begin p 59
###xml 252 256 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1463 1465 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
Tissue (50-100 mg) was homogenised in 1 ml of QIAzol Lysis Reagent (Qiagen, Crawley, UK), using a bench-top homogeniser (Polytron PT1600E, Kinematica AG, Littau-Luzem, Switzerland). Total RNA was isolated from homogenised breast tissue using the RNeasy(R) Tissue Mini Kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. RNA was eluted in 60 mul nuclease-free water and stored at -80degreesC. In addition to the on-column DNase treatment performed during the RNA extraction procedure, RNA was DNase-treated after extraction using the DNA-freetrade mark DNase Treatment and Removal Reagents (Ambion, Cambridgeshire, UK). RNA concentration and purity was assessed in duplicate samples using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, DE, USA). RNA integrity was assessed using the RNA 6000 Nano LabChip Series II Assay with the 2100 Bioanalyzer System (Agilent Technologies, Palo Alto, CA, USA). Electropherograms and gel-like images were evaluated using the Agilent 2100 Expert software (Version B.02.03) which generated the RNA integrity number (RIN) enabling estimation of RNA integrity. The RIN value describes a graded scale of RNA integrity ranging from 1 (completely degraded total RNA) to 10 (intact total RNA). Based on this tool, total RNA integrity is determined not only by the ratio of the ribosomal bands but by the entire electrophoretic trace of the sample including presence or absence of degradation products [49].
###end p 59
###begin p 60
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 156 158 156 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 166 168 166 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 376 377 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 377 380 375 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">260</sub>
###xml 381 382 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 382 386 380 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">280 </sub>
###xml 428 429 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 429 432 427 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">260</sub>
###xml 433 434 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 434 438 432 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">230 </sub>
In agreement with recent reports [34,35], there was a significant negative linear relationship between RNA integrity, as determined by analysis of RIN and Ct values (P < 0.05), with increased Ct values associated with RIN less than 5 (data not shown). Therefore the threshold RIN value for inclusion of RNA samples in analysis was >/= 7. RNA purity was verified by an average A260/A280 ratio of 1.98, ranging from 1.97 to 2.01. A260/A230 ratios averaged 1.7, ranging from 1.5 to 1.83.
###end p 60
###begin title 61
First strand cDNA synthesis by reverse transcription
###end title 61
###begin p 62
###xml 204 205 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">9</sub>
First strand cDNA was synthesised in duplicate reactions for each RNA sample (2 by 1 mug each) using Superscript III reverse transcriptase (Invitrogen Life Technologies, Paisley, UK) and random primers (N9; 1 mug; MWG Biotech, AG, Ebersberg, Germany). Negative controls consisting of non-reverse transcribed samples were included in each set of reactions. The reactions were incubated at 25degreesC for 5 min followed by 50degreesC for 1 h and finally 72degreesC for 15 min. Duplicate cDNA reactions were pooled, diluted to 120 mul in nuclease-free water (Invitrogen Life Technologies), aliquotted and stored at -20degreesC till further use.
###end p 62
###begin title 63
Real-time Quantitative PCR
###end title 63
###begin p 64
###xml 79 83 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 118 122 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 162 166 158 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 396 400 390 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 475 476 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 531 533 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 581 586 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1</italic>
###xml 767 771 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 808 812 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1141 1143 1108 1110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
The expression of the 11 candidate EC genes was analysed by RQ-PCR using TaqMan(R) Endogenous Control Assays or TaqMan(R) Gene Expression Assays and the ABI Prism(R) 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). Each gene was tested in triplicate within the same PCR run for the majority of samples, with the remaining samples tested on an additional 96-well plate. TaqMan(R) Endogenous Control Assay and Gene Expression Assay IDs are listed in Table 4. Samples with standard deviations >0.3 from the mean Ct of the triplicates were excluded from analysis. HPRT1, amplified from pooled normal cDNA, was run on each plate to assess inter-assay variation. cDNA (2 mul) from each tumour sample was added to a PCR reaction mix containing 1x TaqMan(R) Universal PCR Master Mix, No AmpErase(R) UNG and 1 mul Endogenous Control Assay or Gene Expression Assay (Applied Biosystems) in a 20 mul reaction volume. Standard cycling conditions were used [95degreesC for 10 minutes, (95degreesC for 15 seconds, 60degreesC for 60 seconds) x 40 cycles]. The inter-assay percent coefficient of variation (%CV) for samples with a mean Ct of 25.81 +/- 0.07 (mean +/- s.e.m.) was 0.81% (n = 15).
###end p 64
###begin title 65
PCR amplification efficiencies
###end title 65
###begin p 66
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">slope </italic>
###xml 84 93 84 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1/<italic>slope </italic></sup>
###xml 157 159 157 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFRC </italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL19</italic>
Percent PCR amplification efficiencies (E) for each assay were calculated as E = (10-1/slope - 1) x 100, using the slope of the semi-log regression plot of Ct versus log input of cDNA (10-fold dilution series of five points) as shown in Table 4. A threshold of 10% above or below 100% efficiency was applied. Amplification efficiencies ranged from 90.9% for TFRC to 107.7% for MRPL19, indicative of approximate exponential efficiencies for these assays.
###end p 66
###begin title 67
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
Conversion of cycle threshold (Ct) to quantity relative to calibrator
###end title 67
###begin p 68
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 145 147 145 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 439 441 439 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 501 504 501 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 590 593 590 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 598 606 598 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;Ct</sup>
###xml 620 622 612 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 625 627 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 642 644 634 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
The baseline (3-15 cycles) and average threshold cycle (Ct) were automatically calculated using the ABI Prism SDS Software (version 1.2.3). The Ct value is defined as the PCR cycle number at which the fluorescence generated from amplification of the target gene within a sample increases to a threshold value of 10 times the standard deviation of the baseline emission and is inversely proportional to the starting amount of target cDNA. Ct results were converted into quantities relative to normal (QRel.), and corrected for PCR amplification efficiency (E), using the following formula: QRel. = E-DeltaCt, where DeltaCt = Ct test sample - Ct calibrator sample.
###end p 68
###begin title 69
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
Comparative quantitation of target gene ESR1 relative to endogenous control
###end title 69
###begin p 70
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 79 81 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 114 116 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 120 122 104 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 150 152 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 189 191 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 225 227 209 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 332 346 316 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 648 650 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
To calculate the expression of ESR1, relative to an EC gene(s), the DeltaDeltaCt method was used where DeltaDeltaCt = (Ct target gene, test sample - Ct endogenous control, test sample) - (Ct target gene, calibrator sample - Ct endogenous control, calibrator sample). Fold change in gene expression between groups was calculated as E-DeltaDeltaCt +/- s.e.m. Where target gene expression was normalised using more than one endogenous control, fold change estimates were calculated using the geometric mean of EC quantities relative to the calibrator sample and the errors were calculated following the rules of error propagation descibed previously [25].
###end p 70
###begin title 71
Analysis of EC stability
###end title 71
###begin p 72
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 154 156 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 324 328 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 387 389 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 417 421 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 458 460 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
Candidate EC gene stability was evaluated using two statistical models for the analysis candidate EC genes, geNorm [[24], Ver. 3.4] and NormFinder [26]. Ct values were converted into relative quantities considering the PCR amplification efficiencies as detailed above. GeNorm is a Visual Basic application tool for Microsoft(R) Excel and is freely available by request from the authors [50]. NormFinder is a Microsoft(R) Excel add-in, also freely available [51]. For NormFinder analysis tissues samples were categorised into benign (n = 6) or malignant groups (n = 21) according to analysis of standard histopathological parameters as described above.
###end p 72
###begin title 73
Statistical analyses
###end title 73
###begin p 74
###xml 48 52 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 87 91 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 121 123 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 239 241 235 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 389 392 385 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
###xml 704 709 700 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
Statistical analyses were performed with Minitab(R) 15 Statistical Software for Windows(R) (Minitab Ltd., Coventry, UK). P values <0.05 were considered statistically significant. The Anderson-Darling normality test was applied. Two-sample t tests were used to compare calibrator-scaled EC gene quantities between benign and malignant tissue groups. Equality of variance between scaled EC QRel. values and effect of EC on the estimate of the error associated with gene expression was analysed using Bartlett's test. Associations between scaled EC and target gene quantities were determined by regression analysis which examined linear, quadratic and cubic relationships. One-way ANOVA was used to compare ESR1 expression normalised using different EC genes.
###end p 74
###begin title 75
Abbreviations
###end title 75
###begin p 76
RQ-PCR, Real-time quantitative polymerase chain reaction
###end p 76
###begin p 77
EC, endogenous control
###end p 77
###begin p 78
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
Ct, cycle threshold
###end p 78
###begin p 79
RIN, RNA integrity number
###end p 79
###begin p 80
###xml 1 4 1 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Rel</sub>
QRel., quantity of gene expression relative to normal
###end p 80
###begin p 81
NF, geNorm normalisation factor
###end p 81
###begin p 82
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
V, geNorm pairwise variation
###end p 82
###begin p 83
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
M, geNorm stability measure
###end p 83
###begin p 84
T, size or extent of primary tumour
###end p 84
###begin p 85
N, spread to regional lymph nodes
###end p 85
###begin p 86
M, distant metastasis
###end p 86
###begin p 87
UICC, tumour stage according to the International Union Against Cancer TNM classification
###end p 87
###begin p 88
ER, oestrogen receptor
###end p 88
###begin p 89
PR, progesterone receptor
###end p 89
###begin p 90
###xml 5 8 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene
###end p 90
###begin title 91
Authors' contributions
###end title 91
###begin p 92
REM conceived, designed and performed the experiments, was responsible for data analyses and for writing the manuscript. NM contributed throughout the experiment and critically reviewed the manuscript. MJK participated throughout as Head of Department, particularly in sample acquisition during surgery and in critically reviewing the manuscript. All authors read and approved the final manuscript.
###end p 92
###begin title 93
Acknowledgements
###end title 93
###begin p 94
This work was funded by the National Breast Cancer Research Institute (NBCRI) who we wish to thank for their continued generous support. We gratefully acknowledge the assistance of Ms. Catherine Curran in collating the clinical and histological data and Ms. Emer Hennessy, curator of the Department of Surgery, NUI, Galway BioBank. We also thank Ms. Jill Sales, Biomathematics & Statistics Scotland, for her advice and help with the data analysis.
###end p 94
###begin article-title 95
Simultaneous amplification and detection of specific DNA sequences
###end article-title 95
###begin article-title 96
Kinetic PCR analysis: real-time monitoring of DNA amplification reactions
###end article-title 96
###begin article-title 97
Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream
###end article-title 97
###begin article-title 98
The power of real-time PCR
###end article-title 98
###begin article-title 99
Tech.Sight. A technique whose time has come
###end article-title 99
###begin article-title 100
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay
###end article-title 100
###begin article-title 101
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer
###end article-title 101
###begin article-title 102
###xml 63 68 <span type="species:ncbi:9606">human</span>
Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization
###end article-title 102
###begin article-title 103
###xml 53 58 <span type="species:ncbi:9606">human</span>
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success
###end article-title 103
###begin article-title 104
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
###end article-title 104
###begin article-title 105
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
###end article-title 105
###begin article-title 106
NCOR1 mRNA is an independent prognostic factor for breast cancer
###end article-title 106
###begin article-title 107
Real-time RT-PCR normalisation; strategies and considerations
###end article-title 107
###begin article-title 108
###xml 59 62 <span type="species:ncbi:10116">rat</span>
Up-regulation of beta-actin, cyclophilin and GAPDH in N1S1 rat hepatoma
###end article-title 108
###begin article-title 109
###xml 94 99 <span type="species:ncbi:9606">human</span>
Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in late pathological stage human prostate cancer
###end article-title 109
###begin article-title 110
Thyrotropin-releasing hormone increases the levels of c-fos and beta-actin mRNA in GH3/B6 pituitary tumor cells
###end article-title 110
###begin article-title 111
Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter
###end article-title 111
###begin article-title 112
###xml 74 79 <span type="species:ncbi:9606">human</span>
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers
###end article-title 112
###begin article-title 113
###xml 186 191 <span type="species:ncbi:9606">human</span>
Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations
###end article-title 113
###begin article-title 114
Differential expression patterns of beta-actin mRNA in cells undergoing apoptosis
###end article-title 114
###begin article-title 115
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?
###end article-title 115
###begin article-title 116
Beta actin expression and organization of actin filaments in colorectal neoplasia
###end article-title 116
###begin article-title 117
The real-time polymerase chain reaction
###end article-title 117
###begin article-title 118
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
###end article-title 118
###begin article-title 119
GeNorm software manual, update 13th March 2007
###end article-title 119
###begin article-title 120
Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
###end article-title 120
###begin article-title 121
###xml 100 105 <span type="species:ncbi:9606">human</span>
Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction
###end article-title 121
###begin article-title 122
Statistical modeling for selecting housekeeper genes
###end article-title 122
###begin article-title 123
###xml 47 52 <span type="species:ncbi:9606">women</span>
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
###end article-title 123
###begin article-title 124
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
###end article-title 124
###begin article-title 125
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer
###end article-title 125
###begin article-title 126
Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement
###end article-title 126
###begin article-title 127
RNA polymerases I and III, growth control and cancer
###end article-title 127
###begin article-title 128
RNA integrity and the effect on the real-time qRT-PCR performance
###end article-title 128
###begin article-title 129
Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR
###end article-title 129
###begin article-title 130
Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction
###end article-title 130
###begin article-title 131
Quantification of mRNA using real-time RT-PCR
###end article-title 131
###begin article-title 132
Statistical analysis of real-time PCR data
###end article-title 132
###begin article-title 133
Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR
###end article-title 133
###begin article-title 134
Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes
###end article-title 134
###begin article-title 135
Choice of endogenous control for gene expression in nonsmall cell lung cancer
###end article-title 135
###begin article-title 136
###xml 100 105 <span type="species:ncbi:9606">human</span>
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer
###end article-title 136
###begin article-title 137
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
###end article-title 137
###begin article-title 138
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR
###end article-title 138
###begin article-title 139
Tumor classification using gene expression patterns from DNA microarrays
###end article-title 139
###begin article-title 140
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 140
###begin article-title 141
Computational method for discovery of estrogen responsive genes
###end article-title 141
###begin article-title 142
Real-time, fluorescence-based quantitative PCR: a snapshot of current procedures and preferences
###end article-title 142
###begin article-title 143
RNA integrity number (RIN) - standardization of RNA quality control.
###end article-title 143
###begin article-title 144
geNorm
###end article-title 144
###begin article-title 145
NormFinder
###end article-title 145

